Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Historisch | Analysen | |||||
Ausblick |
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 88.00 |
Vanguard Health Care Fund | 0.86 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 121’597 | 125’161 | 103’914 | 105’794 | 104’323 |
Umsatz pro Mitarbeiter in Mio. EUR | 0.40 | 0.41 | 0.45 | 0.43 | 0.45 |
Bilanz (in Mio. EUR) - Aktiva
2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 27’489 | 35’058 | 28’570 | 26’229 | 41’656 |
Summe Anlagevermögen | 99’977 | 109’132 | 81’944 | 83’492 | 89’912 |
Summe Aktiva | 129’833 | 143’578 | 114’665 | 116’848 | 123’811 |
Bilanz (in Mio. EUR) - Passiva
2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 27’700 | 31’634 | 28’225 | 33’462 | 28’268 |
Summe Fremdkapital | 57’498 | 66’003 | 60’872 | 66’759 | 62’015 |
Summe Eigenkapital | 72’334 | 77’575 | 53’793 | 50’090 | 61’796 |
Summe Passiva | 129’833 | 143’578 | 114’665 | 116’848 | 123’811 |
Adresse
Lichtstrasse 35, 4056 Basel | |
Telefon | +41 (61) 324-11-11 |
Fax | +41 (61) 324-80-01 |
Internet | http://www.novartis.com |
Management
Ana de Pro Gonzalo
Non-Executive Director |
Andreas von Planta
Independent Non-Executive Director |
Bridgette P. Heller
Director |
Charles L. Sawyers
Independent Non-Executive Director |
Charlotte Pamer-Wieser
Secretary |
Daniel Hochstrasser
Director |
Frans van Houten
Independent Non-Executive Director |
Hans Jörg Reinhardt
Non-Executive Chairman |
Harry Werner Kirsch
Chief Financial Officer |
Karen L. Hale
Chief Legal Officer |
Kees Roks
Chief Audit Officer |
Klaus Moosmayer
Chief Ethics, Risk & Compliance Officer |
Linda Kanitra
Associate Director-Drug Development |
Lutz Hegemann
Chief Strategy & Growth Officer |
Marco Gadola
Senior Auditor |
Marie-France Tschudin
Chief Commercial Officer |
Mary Elizabeth Doherty
Independent Non-Executive Director |
Nancy C. Andrews
Independent Non-Executive Director |
Natacha Theytaz
Head-Internal Audit |
Patrice Bula
Lead Independent Director |
Robert Kowalski
Chief People & Organization Officer |
Samir Shah
Global Head-Investor Relations |
Shreeram Aradhye
Chief Medical Officer |
Simon E. Moroney
Vice Chairman |
Steffen Lang
President-Operations |
Ton Büchner
Independent Non-Executive Director |
Vasant Narasimhan
Chief Executive Officer |
William Thomas Winters
Independent Non-Executive Director |